Australia produces world-class science; too much of it stalls in the lab. Proto Axiom exists to change that. We co-create new biotech companies with researchers, supply the first institutional capital, and stay at the table until the science reaches patients.
While many Australian funds have not met market expectations despite significant government backing, Proto Axiom operates with discipline and transparency. We emphasize a sustainable financial path, hand in hand with achieving technical milestones.
We scout universities, medical research institutes and hospitals for ideas with genuine therapeutic promise, not just publications.
In short sprints we test the core hypothesis, map the IP, and design an execution plan with the founding scientists.
Proto Axiom wires the first cheque and recruits an operator-scientist to run day-to-day development.
We underwrite the pivotal experiments—GLP tox, IND-enabling work, early device builds—so later investors see a clean, data-driven story.
When a program is Phase 1-ready, we syndicate follow-on rounds with top VCs and, where relevant, big-pharma strategics.
Proto Axiom Connect provides member institutes, researchers and entrepreneurs exclusive access to our incubation platform, programming, investment and news.
Join Now